DCM
TRVI icon

Driehaus Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Driehaus Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-117,371
Closed -$386K – 475
2020
Q1 		$386K Sell
117,371
-7,629
-6% -$34.7K 0.01% 316
2019
Q4 		$469K Hold
125,000
– – 0.01% 409
2019
Q3 		$563K Hold
125,000
– – 0.02% 401
2019
Q2 		$938K Buy
+125,000
New +$1.08M 0.03% 278

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $16.1B AUM 40.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Driehaus Capital Management's TRVI Position: Q2 2020 in Review

Driehaus Capital Management sold out of Trevi Therapeutics (TRVI) in Q2 2020, closing a stake of 117,371 shares — an estimated $386K sold.

Driehaus Capital Management first reported a position in TRVI in Q2 2019 and held it in 4 quarters. The position peaked at $938K in Q2 2019. 16 funds tracked by Wall St. Rank hold TRVI as of Q2 2020.

  • Driehaus Capital Management reported no remaining Trevi Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Driehaus Capital Management sold 117,371 Trevi Therapeutics shares in Q2 2020, an estimated $386K.
  • Driehaus Capital Management first reported a position in Trevi Therapeutics in Q2 2019 and held it in 4 quarters.
  • Driehaus Capital Management's Trevi Therapeutics position peaked at $938K in Q2 2019.
  • 16 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2020.

Based on Driehaus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.